$33.10
2.73%
Nasdaq, Aug 29, 10:00 pm CET
ISIN
US98887Q1040
Symbol
ZLAB

Zai Lab Ltd. Unsponsored ADR Stock price

$33.10
-7.41 18.29% 1M
-1.54 4.45% 6M
+6.91 26.38% YTD
+13.55 69.31% 1Y
-10.76 24.53% 3Y
-46.27 58.30% 5Y
+5.17 18.51% 10Y
+5.17 18.51% 20Y
Nasdaq, Closing price Fri, Aug 29 2025
+0.88 2.73%
ISIN
US98887Q1040
Symbol
ZLAB
Industry

Key metrics

Basic
Market capitalization
$3.7b
Enterprise Value
$3.1b
Net debt
positive
Cash
$732.2m
Shares outstanding
1.1b
Valuation (TTM | estimate)
P/E
negative | negative
P/S
8.6 | 6.4
EV/Sales
7.3 | 5.5
EV/FCF
negative
P/B
4.6
Financial Health
Equity Ratio
70.9%
Return on Equity
-30.6%
ROCE
-29.6%
ROIC
-78.9%
Debt/Equity
0.2
Financials (TTM | estimate)
Revenue
$427.8m | $569.0m
EBITDA
$-233.6m | $-167.5m
EBIT
$-246.7m | $-165.8m
Net Income
$-212.5m | $-154.7m
Free Cash Flow
$-231.0m
Growth (TTM | estimate)
Revenue
32.6% | 42.6%
EBITDA
31.9% | 37.9%
EBIT
30.2% | 41.1%
Net Income
28.8% | 39.8%
Free Cash Flow
-5.5%
Margin (TTM | estimate)
Gross
62.5%
EBITDA
-54.6% | -29.4%
EBIT
-57.7%
Net
-49.7% | -27.2%
Free Cash Flow
-54.0%
More
EPS
$-0.2
FCF per Share
$-0.2
Short interest
4.9%
Employees
2k
Rev per Employee
$210.0k
Show more

Is Zai Lab Ltd. Unsponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Zai Lab Ltd. Unsponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Zai Lab Ltd. Unsponsored ADR forecast:

10x Buy
77%
3x Hold
23%

Analyst Opinions

13 Analysts have issued a Zai Lab Ltd. Unsponsored ADR forecast:

Buy
77%
Hold
23%

Financial data from Zai Lab Ltd. Unsponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
428 428
33% 33%
100%
- Direct Costs 161 161
35% 35%
38%
267 267
31% 31%
62%
- Selling and Administrative Expenses 284 284
5% 5%
66%
- Research and Development Expense 230 230
11% 11%
54%
-234 -234
32% 32%
-55%
- Depreciation and Amortization 13 13
27% 27%
3%
EBIT (Operating Income) EBIT -247 -247
30% 30%
-58%
Net Profit -213 -213
29% 29%
-50%

In millions USD.

Don't miss a Thing! We will send you all news about Zai Lab Ltd. Unsponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Zai Lab Ltd. Unsponsored ADR Stock News

Neutral
Business Wire
about 9 hours ago
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the Hong Kong Department of Health has approved TIVDAK (tisotumab vedotin-tftv) in Hong Kong for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. “Today's approval of TIVDAK marks an important milestone for Zai La...
Neutral
Business Wire
5 days ago
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company's senior management team will participate in the following investor conferences in September 2025: Cantor Global Healthcare Conference Presentation: Thursday, September 4, 2025, 10:20 a.m. ET Location: New York, NY Morgan Stanley 23rd Annual Global Healthcare Conf...
Neutral
Business Wire
14 days ago
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the China National Medical Products Administration (NMPA) has granted Innovative Medical Device Designation for Tumor Treating Fields (TTFields) for patients with pancreatic cancer based on the positive results from the Phase 3 PANOVA-3 trial. The Innovative Medical Device Designation a...
More Zai Lab Ltd. Unsponsored ADR News

Company Profile

Zai Lab Ltd. is a biopharmaceutical company, which engages in the licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need. Its product pipelines include ZL-2306, ZL-2401, FPA144, ETX2514, and ZL-2301. The company was founded by Samantha Ying Du and Marietta Wu in 2014 and is headquartered in Shanghai, China.

Head office Cayman Islands
CEO Ying Du
Employees 1,869
Founded 2014
Website www.zailaboratory.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today